Profound Medical Announces Second Quarter 2024 Financial Results
08 août 2024 16h05 HE
|
Profound Medical Corp.
TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow
18 juil. 2024 16h30 HE
|
Profound Medical Corp.
TORONTO, July 18, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases
11 juil. 2024 07h00 HE
|
Profound Medical Corp.
TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
[Latest] Global Cancer Supportive Care Drugs Market Size/Share Worth USD 32,783.2 Billion by 2033 at a 3.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
06 mai 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Supportive Care Drugs Market Size, Trends and Insights By Drug Type...
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
02 avr. 2024 17h46 HE
|
FibroGen, Inc.
FG-3246 demonstrated efficacy in adenocarcinoma selected cohorts receiving biologically active doses of FG-3246 at ≥ 1.2 mg/kg in heavily pre-treated, biomarker unselected patients: Median...
[Latest] Global Cancer Immunotherapy Market Size/Share Worth USD 314.4 Billion by 2032 at a 7.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
28 mars 2024 15h30 HE
|
Custom Market Insights
Austin, TX, USA, March 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Immunotherapy Market Size, Trends and Insights By Type of Immunotherapy...
[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
27 mars 2024 14h30 HE
|
Custom Market Insights
Austin, TX, USA, March 28, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “PARP Inhibitors Market Size, Trends and Insights By Type (Olaparib, Rucaparib,...
[Latest] Global Proton Therapy Market Size/Share Worth USD 2,405.6 Million by 2032 at a 12.11% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
07 mars 2024 11h30 HE
|
Custom Market Insights
Austin, TX, USA, March 07, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Proton Therapy Market Size, Trends and Insights By Setup Type (Single-Room...
Blackford and Bot Image Announce Partnership to Enhance Prostate Cancer Care
16 janv. 2024 10h01 HE
|
Blackford
Blackford and Bot Image Announce Partnership to Enhance Prostate Cancer Care
Cepham’s Prosprune Protects Men and Sustains the Environment in the Name of Prostate Health
18 juil. 2023 08h28 HE
|
Cepham
CHANDIGARH, India, July 18, 2023 (GLOBE NEWSWIRE) -- Researchers at Cepham, an innovative leader in nutraceuticals research and branded ingredients, have developed a patent-pending hydro-ethanolic...